ArticleChemMedChem2022
Promising Therapeutic Approach for SARS-CoV-2 Infections by Using a Rutin-Based Combination Therapy.
Article in ChemMedChem, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 13 citations in OpenAlex.
- Bioactive Compounds ofInternational journal of molecular sciences · 2026Article
- Fisetin as an Antiviral Agent Targeting the RNA-Dependent RNA Polymerase of SARS-CoV-2: Computational Prediction and In Vitro Experimental Validation.Microorganisms · 2025Article
- Crystal structures of 3,4,5-tri-phenyl-toluene and 3,4,5-tri-phenyl-benzyl bromide.Acta crystallographica. Section E, Crystallographic communications · 2025Article
- Identification ofMolecules (Basel, Switzerland) · 2025Article
- IntegratedCurrent medicinal chemistry · 2025Article
- Rutin prevents EqHV-8 induced infection and oxidative stress via Nrf2/HO-1 signaling pathway.Frontiers in cellular and infection microbiology · 2024Article
- Promising Therapeutic Approach for SARS-CoV-2 Infections by Using a Rutin-Based Combination Therapy.ChemMedChem · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of new therapeutic approaches for SARS-CoV-2 infections is of particular current importance. The combination therapy proposed here is based on already proven, safe and inexpensive compounds. The natural compound rutin, one of the six therapy components, has the potential to inhibit both viral and host cell targets. In addition, this therapy involves the use of acetylsalicylic acid, vitamin C and vitamin D
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.